All Posts by

Leslie Merryman

Essential Tremor: Evolving Innovations in Treatment Advanced Options

Essential tremor is the most prevalent movement disorder, affecting up to 4% of the general population. Although the exact cause remains largely unknown, about half of all cases are familial, and transmission is most consistent with an autosomal dominant mechanism. Essential tremor progresses slowly over time and can result in…

UF Health now offers drug that might slow Alzheimer’s disease

University of Florida Health is offering a new drug therapy that could temporarily slow the progression of Alzheimer’s disease in some patients. Lecanemab is thought to successfully target and eliminate clusters of sticky proteins, or amyloid plaques, that form between the brain’s nerve cells and play an important part in…

Ribosome Profiling and Mass Spectrometry Reveal Widespread Mitochondrial Translation Defects in a Striatal Cell Model of Huntington Disease

Congratulations to Dr. Srinivasa Subramaniam on the publication of “Ribosome Profiling and Mass Spectrometry Reveal Widespread Mitochondrial Translation Defects in a Striatal Cell Model of Huntington Disease,” which appears in the April edition of Molecular and Cellular Proteomics. Abstract Huntington disease (HD) is caused by an expanded polyglutamine mutation in…

The History of the Term “Catatonia” in Cases of Encephalopathy

Congratulations to Drs. Visual Perera and Michael Okun on the publication of “The History of the Term “Catatonia” in Cases of Encephalopathy,” which appears in the April edition of Neurology. Abstract Objective: The neuropsychiatric term catatonia was born in the 19th century. We explored primary source documents to define the founder’s…

Real-world Outcomes Using DBS Systems with Directionality and Multiple Independent Current Control: USA Experience 

Congratulation to Drs. Michael Okun and Kelly Foote, on the publication of “Real-world Outcomes Using DBS Systems with Directionality and Multiple Independent Current Control: USA Experience,” which appears in the April edition of Neurology. Abstract Objective: Here, we present preliminary outcomes from an ongoing prospective, multicenter outcomes registry conducted at…

SUMO modifies GβL and mediates mTOR signaling

Congratulations to Dr. Srinavasa Subramaniam on the publication of “SUMO modifies GβL and mediates mTOR signaling,” which appears in the April edition of the Journal of Biological Chemistry. Introduction The mechanistic target of rapamycin (mTOR) signaling is influenced by multiple regulatory proteins and post-translational modifications; however, underlying mechanisms remain…

Diabetes drug shows promise against Parkinson’s in clinical study

Michael Okun, medical director of the Parkinson’s Foundation, told AFP that from a practical standpoint, the differences in patient outcomes were not clinically significant, but “statistically and compared to other studies, this type of difference should draw our interest and attention.” “Experts will likely argue whether this study meets a…

UF team plays major role in success of newly approved Duchenne muscular dystrophy drug

 Duchenne muscular dystrophy families, advocates and health care providers celebrated a milestone in March with the U.S. Food and Drug Administration’s approval of the first nonsteroidal drug for the treatment of Duchenne. In findings published in the April issue of The Lancet Neurology, a team of investigators led by pharmaceutical company Italfarmaco,…